Mulye took a moment to defend Martin Shkreli, who gained notoriety for buying exclusive rights to another decades-old drug and ruthlessly raised its price by more than 5,000 percent virtually overnight
This is what happens when non-pharma development CEOs run drug companies, essentially this company is a patent troll. People who have not actually been involved in the development of drugs (where you actually meet an interact with physicians and patients)may unfortunately disassociate the drugs with the people that need them.
Also it should be noted that Nostrum is not actually selling the drug because it does not meet FDA purity standards so the "price hike" is just on paper for now but his comments will definitely spark quick approval of a generic competitor.
>Mulye took a moment to defend Martin Shkreli, who gained notoriety for buying exclusive rights to another decades-old drug and ruthlessly raised its price by more than 5,000 percent virtually overnight
This is what happens when non-pharma development CEOs run drug companies, essentially this company is a patent troll. People who have not actually been involved in the development of drugs (where you actually meet an interact with physicians and patients)may unfortunately disassociate the drugs with the people that need them.
Also it should be noted that Nostrum is not actually selling the drug because it does not meet FDA purity standards so the "price hike" is just on paper for now but his comments will definitely spark quick approval of a generic competitor.
https://www.biopharmadive.com/news/gottlieb-rebuffs-pharma-ceo-nostrum-labs-price-hikes-moral-imperative/532194/
No memes or images. Exceptions may be made in the case of images of an ongoing news story becoming available.
User-edited titles are not allowed. Copy the headline directly and use it as the post title. Corrections in spelling or minor alterations may be acceptable.
News articles written over a month before posting must have the date of the article in the post title.
No paywalls. Use an archived link to post a paywalled article.
This is what happens when non-pharma development CEOs run drug companies, essentially this company is a patent troll. People who have not actually been involved in the development of drugs (where you actually meet an interact with physicians and patients)may unfortunately disassociate the drugs with the people that need them.
Also it should be noted that Nostrum is not actually selling the drug because it does not meet FDA purity standards so the "price hike" is just on paper for now but his comments will definitely spark quick approval of a generic competitor.
https://www.biopharmadive.com/news/gottlieb-rebuffs-pharma-ceo-nostrum-labs-price-hikes-moral-imperative/532194/